Penta at IAS 2025 Conference on HIV Science
| Date and time (CAT) | Session | Title | Presenter |
| Wednesday 16 July, 10:45-11:45 AM | Special issues in paediatrics | Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial | James Wyncoll |
| Wednesday 16 July, 3 PM | Co-Chair’s choice | BREATHER Plus results | Adeodata R. Kekitiinwa |
International Workshop on Pediatrics & HIV 2025
| Date and time (CAT) | Session | Title | Presenter |
| Saturday 12 July, 8:55 AM | Oral Abstract Presentations III | Effectiveness and safety of dolutegravir (DTG) in infants and children aged under 12-years at start of DTG in Europe and Thailand
| Jeannie Collins
|
| Saturday 12 July, 8:55 AM | Oral Abstract Presentations III | Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial | James Wyncoll |
| Saturday 12 July, 8:55 AM | Oral Abstract Presentations III | Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials | Pauline Amuge |
| Saturday 12 July, 12:05 PM | Oral Abstract Presentations IV | Growth Trajectories Before and After Switching to Dolutegravir in Children Living with HIV in the ODYSSEY Trial
| Man Chan |
| Friday 11 July – Saturday 12 July | Poster number: 86
| Mortality rates and associated factors among people living with perinatally acquired HIV in Europe and Thailand | John O’Rourke
|
| Friday 11 July – Saturday 12 July | Poster number: 123
| Growth outcomes in children living with HIV in Europe and Thailand before and after starting dolutegravir
| Kate Edgar
|
| Friday 11 July – Saturday 12 July | Poster number: 26 | Pregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert | Grace Miriam Ahimbisibwe |